Infanrix Polio (Poliovirus (Inactivated) Type 3 (Saukett Strain), Pertussis Filamentous Haemagglutinin Adsorbed On A)

The vaccine contains inactivated poliovirus type 3 particles and purified pertussis filamentous haemagglutinin. After intramuscular injection, these antigens stimulate the immune system to produce specific antibodies that neutralise poliovirus and block pertussis adhesion, thereby establishing active immunity.

The dosage and schedule of Infanrix Polio are determined by the prescribing healthcare professional based on national immunisation guidelines and the patient’s age. The prescriber sets the exact amount and timing of each injection.

Safety data for Infanrix Polio in pregnancy are limited, and the vaccine is generally not recommended unless the potential benefit outweighs the risk. Limited information is available for breastfeeding mothers, but the vaccine is not expected to pose a risk to the infant.

To place an order, submit an enquiry on the Infanrix Polio product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Infanrix Polio combines inactivated poliovirus type 3 with pertussis antigens, offering dual protection in a single injection. Compared with monovalent polio vaccines, it reduces the number of injections required but follows similar safety and efficacy principles for poliovirus immunity.

Infanrix Polio must be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The vaccine should be kept in its original packaging until use to maintain potency.

The vaccine is given by a single intramuscular injection, typically into the anterolateral thigh in infants or the deltoid muscle in older children, according to the immunisation schedule recommended by health authorities.

Serious but rare adverse events include severe allergic reactions (anaphylaxis), seizures, high‑grade fever, encephalopathy, and Guillain‑Barré syndrome. Any signs of a serious reaction should be reported to a healthcare professional immediately.

Infanrix Polio should be avoided in individuals with a known severe allergy to any vaccine component, in infants younger than the approved age, and in persons who have experienced a severe reaction to a previous dose of the same vaccine.